2024
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, DOI: 10.1111/pcmr.13188.Peer-Reviewed Original ResearchSite of metastasisPattern of metastatic diseaseMelanoma mortalityRetrospective observational cohort studyCause of cancer mortalityDistant lymph nodesObservational cohort studyDiagnosis to deathImmunotherapy eraAdvanced melanomaMetastatic diagnosisMetastatic diseaseMetastatic melanomaImmunotherapy treatmentRespiratory failureCause of deathMedian timeLymph nodesTherapeutic advancesCohort studyMelanomaImmunotherapyMechanism of deathPatientsEnd of lifeNCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024.
Schmults C, Blitzblau R, Aasi S, Alam M, Amini A, Bibee K, Bolotin D, Bordeaux J, Chen P, Contreras C, DiMaio D, Donigan J, Farma J, Ghosh K, Harms K, Ho A, Lukens J, Manber S, Mark L, Medina T, Nehal K, Nghiem P, Olino K, Park S, Patel T, Puzanov I, Rich J, Sekulic A, Shaha A, Srivastava D, Thomas V, Tomblinson C, Venkat P, Xu Y, Yu S, Yusuf M, McCullough B, Espinosa S. NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2024, 22: e240002. PMID: 38244274, DOI: 10.6004/jnccn.2024.0002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsLocally advanced diseaseMerkel cell carcinomaAdvanced diseaseLocally advanced Merkel cell carcinomaAdvanced Merkel cell carcinomaNode negative statusSystemic therapy optionsIn-transit diseaseNCCN Guidelines InsightsCell carcinomaNCCN GuidelinesClinical stageDiagnostic workupTherapy optionsTreatment optionsNegative statusInstitutional reviewNCCNDiseaseGuidelinesOptionsCarcinomaWorkupPatientsPanel members
2023
Impact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatientsCase report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases
Rusheen J, Clune J, Ariyan S, Baumann R, Kluger H, Olino K, Weiss S. Case report: Metastatic Merkel cell carcinoma presenting seven years after loco-regional disease resection of primary tumor with interval in-transit and nodal metastases. Frontiers In Oncology 2023, 13: 1217816. PMID: 37476373, PMCID: PMC10354444, DOI: 10.3389/fonc.2023.1217816.Peer-Reviewed Case Reports and Technical NotesMerkel cell carcinomaDuration of surveillanceLate recurrenceCell carcinomaMetastatic Merkel cell carcinomaPrimary Merkel cell carcinomaMetastases 15 monthsSuch late recurrencesPredictors of recurrenceNodal recurrenceDefinitive therapyFirst recurrenceDisease resectionNodal metastasisPhysical examinationRare tumorPrimary diagnosisPrimary tumorRisk factorsHigh riskNational guidelinesRecurrenceOptimal durationPatientsCarcinomaMalignant Melanoma in Older Adults: Different Patient or Different Disease?
Sasson D, Smetona J, Parsaei Y, Papageorge M, Ariyan S, Olino K, Clune J. Malignant Melanoma in Older Adults: Different Patient or Different Disease? Cureus 2023, 15: e34742. PMID: 36909026, PMCID: PMC9998075, DOI: 10.7759/cureus.34742.Peer-Reviewed Original ResearchMelanoma-specific survivalRecurrence-free survivalOlder patientsT2 tumorsNodal positivityMetastatic progressionOlder adultsConclusion Older adultsLog-rank testingKaplan-Meier analysisT4 tumorsYounger patientsT1 tumorsBreslow thicknessClinical outcomesTumor characteristicsTumor thicknessSingle institutionClinical behaviorMalignant melanomaLower incidenceHigh incidencePatientsConsecutive sampleAge groupsCurrent diagnosis and management of cardiac melanoma: a case series and review
Long A, Chang J, Glahn J, Olino K, Tran T, Clune J. Current diagnosis and management of cardiac melanoma: a case series and review. Journal Of Cancer Metastasis And Treatment 2023, 9: null-null. DOI: 10.20517/2394-4722.2022.113.Peer-Reviewed Original ResearchUse of immunotherapyCardiac melanomaCardiac tumorsSurveillance imagingMalignant melanomaRoutine surveillance imagingCardiac metastasisCase seriesCDKN2A variantsClinical findingsAutopsy studyBRAF mutationsNRAS mutationsPatientsCurrent diagnosisImmunotherapyMelanomaGenetic profilingHigh rateTumorsDiagnosisImagingMetastasisTherapySymptoms
2022
Unmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma
Leonard L, Beaty L, Thomas M, Quinn C, Colborn K, de Araujo T, Torphy R, Assumpção L, Olino K, Studts C, Franco S, McCarter M, Stewart C, Gleisner A. Unmeasured factors are associated with the use of completion lymph node dissection (CLND) in melanoma. Journal Of Surgical Oncology 2022, 127: 716-726. PMID: 36453464, DOI: 10.1002/jso.27153.Peer-Reviewed Original ResearchConceptsCompletion lymph node dissectionSentinel lymph nodesPositive sentinel lymph nodesLymph node dissectionNode dissectionMultivariable mixed-effects logistic regression modelGovernment-based insuranceNational Cancer DatabasePrimary tumor locationStage III melanomaEffect of patientContribution of patientMixed effects logistic regression modelsLogistic regression modelsTumor factorsOlder patientsSurvival benefitLymph nodesSurgical excisionStandard treatmentTumor locationCancer DatabasePatient variablesPatientsLower limbs
2020
Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series
Ligtenberg KG, Hu JK, Damsky W, Olino K, Kluger H, Clune J, Cowper SE, Panse G, Leventhal J, Weiss SA. Neoadjuvant anti–programmed cell death 1 therapy for locally advanced basal cell carcinoma in treatment-naive patients: A case series. JAAD Case Reports 2020, 6: 628-633. PMID: 32613057, PMCID: PMC7317689, DOI: 10.1016/j.jdcr.2020.05.010.Peer-Reviewed Case Reports and Technical NotesAssessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Park H, Young M, Olino K, Rahmati R, Mehra S, Burtness B, Judson B. Assessment of Lymph Node Evaluation in Patients with Clinically Node Negative Merkel Cell Carcinoma of the Head and Neck. International Journal Of Radiation Oncology • Biology • Physics 2020, 106: 1191-1192. DOI: 10.1016/j.ijrobp.2019.11.099.Peer-Reviewed Original Research
2016
Palliative Care for Pancreatic and Periampullary Cancer
Perone JA, Riall TS, Olino K. Palliative Care for Pancreatic and Periampullary Cancer. Surgical Clinics Of North America 2016, 96: 1415-1430. PMID: 27865285, PMCID: PMC5119929, DOI: 10.1016/j.suc.2016.07.012.Peer-Reviewed Original ResearchConceptsMost patientsPalliative careGastric outlet obstructionRelief of painPancreatic cancer patientsAdvanced diseaseLocalized diseaseMultimodality therapyCeliac plexusOutlet obstructionPeriampullary cancerObstructive jaundiceCancer patientsPancreatic cancerPalliative techniquesPatientsCommon endpointCancerDiseaseReliefCareCare triangleFamily goalsJaundicePainIncidence of hepaticojejunostomy stricture after hepaticojejunostomy
Dimou FM, Adhikari D, Mehta HB, Olino K, Riall TS, Brown KM. Incidence of hepaticojejunostomy stricture after hepaticojejunostomy. Surgery 2016, 160: 691-698. PMID: 27392391, PMCID: PMC5429863, DOI: 10.1016/j.surg.2016.05.021.Peer-Reviewed Original ResearchConceptsBiliary-enteric anastomosisStricture formationBiliary-enteric anastomotic stricturesCox proportional hazards modelManagement of stricturesProportional hazards modelCumulative incidence curvesMedicare claims dataUse of imagingStricture diagnosisCumulative incidenceAnastomotic strictureHepaticojejunostomy stricturesPostoperative strictureTrue incidenceClaims dataHazards modelPatientsStrictureAnastomosisDecreased likelihoodYounger ageIncidence curvesIncidenceMean time
2015
Right Colectomy Procedure Guide
Olino K, Samdani T, Garcia-Aguilar J. Right Colectomy Procedure Guide. 2015, 121-131. DOI: 10.1007/978-3-319-09120-4_10.Chapters
2014
A preclinical murine model of hepatic metastases.
Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L. A preclinical murine model of hepatic metastases. Journal Of Visualized Experiments 2014, 51677. PMID: 25285458, PMCID: PMC4378377, DOI: 10.3791/51677.Peer-Reviewed Original ResearchConceptsHepatic metastasesMurine modelNumerous murine modelsPreclinical murine modelsTumor immunology researchPancreatic tumor modelPancreatic tumor cellsMurine pancreatic tumor modelMetastatic diseaseClinical conditionsMetastatic processTumor modelTherapy testingTumor cellsCancer treatmentMetastasisHuman cancersImmunology researchLiverModel mimicsPatientsCancerDiseaseMiceA Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors
Ellison TA, Wolfgang CL, Shi C, Cameron JL, Murakami P, Mun LJ, Singhi AD, Cornish TC, Olino K, Meriden Z, Choti M, Diaz LA, Pawlik TM, Schulick RD, Hruban RH, Edil BH. A Single Institution's 26-Year Experience With Nonfunctional Pancreatic Neuroendocrine Tumors. Annals Of Surgery 2014, 259: 204-212. PMID: 23673766, PMCID: PMC4048026, DOI: 10.1097/sla.0b013e31828f3174.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsStaging systemSimple prognostic toolNeuroendocrine tumorsPrognostic toolStage IFive-year overall survival rateNonfunctional pancreatic neuroendocrine tumorsMain staging systemsAJCC stage ITumor staging systemOverall survival rateAmerican Joint CommitteeSingle-institution seriesKi-67 labelingPrognostic factorsSurvival prognosticationSingle institutionJoint CommitteeMultivariate analysisNatural historyComparison of reportsPatientsNeoplasmsSurvival
2013
Missing Consent Forms in the Preoperative Area: A Single-Center Assessment of the Scope of the Problem and Its Downstream Effects
Garonzik-Wang JM, Brat G, Salazar JH, Dhanasopon A, Lin A, Akinkuotu A, O’Daly A, Elder B, Olino K, Burns W, Camp M, Lipsett PA, Freischlag JA, Haut ER. Missing Consent Forms in the Preoperative Area: A Single-Center Assessment of the Scope of the Problem and Its Downstream Effects. JAMA Surgery 2013, 148: 886-889. PMID: 23842781, DOI: 10.1001/jamasurg.2013.354.Peer-Reviewed Original Research
2012
Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas
Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2012, 255: 326-333. PMID: 22167000, PMCID: PMC3534752, DOI: 10.1097/sla.0b013e3182378a18.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryClone CellsFemaleHumansLaser Capture MicrodissectionLoss of HeterozygosityMaleMiddle AgedMutationNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRetrospective StudiesSequence Analysis, DNAConceptsMultifocal intraductal papillary mucinous neoplasmsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmMucinous neoplasmsClinicopathologic featuresPancreatic cancerClonal relationshipBranch duct lesionsCystic precursor lesionsFamilial pancreatic cancerKRAS gene mutationsIntermediate dysplasiaIndependent genetic alterationsDuct lesionsClinicopathological characteristicsInvasive cancerPrecursor lesionsPartial pancreatectomyPatientsNeoplasmsIntermediate gradeGene mutationsCancerGenetic alterationsMolecular analysis
2011
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2011, 118: 2674-2681. PMID: 21935914, PMCID: PMC3578343, DOI: 10.1002/cncr.26553.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaConditional survivalConditional survival estimatesActuarial survivalCurative intentPositive marginsSurvival estimatesDuctal adenocarcinomaResection of PDACPostoperative year 5Date of surgeryCox regression analysisPredictors of survivalTime of surgeryMedian survivalMargin statusWorse survivalHigher lymphKaplan-MeierTumor sizeLarge cohortPatientsMultivariate analysisLymphSurgery
2010
EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors
Khashab MA, Yong E, Lennon AM, Shin EJ, Amateau S, Hruban RH, Olino K, Giday S, Fishman EK, Wolfgang CL, Edil BH, Makary M, Canto MI. EUS is still superior to multidetector computerized tomography for detection of pancreatic neuroendocrine tumors. Gastrointestinal Endoscopy 2010, 73: 691-696. PMID: 21067742, DOI: 10.1016/j.gie.2010.08.030.Peer-Reviewed Original ResearchConceptsPancreatic neuroendocrine tumorsNeuroendocrine tumorsRetrospective single-center cohort studySingle-center cohort studyMost pancreatic neuroendocrine tumorsCT detection rateMultidetector computerized tomographySensitivity of CTJohns Hopkins HospitalSensitivity of EUSDetection rateDetection of PNETsCT technologyCohort studyRole of EUSReferral biasPreoperative CTMultidetector CTComputerized tomographyNonrandomized designPancreatic imagingInsulinomaTumorsPatientsCT imagingThe Effect of Steatosis on Echogenicity of Colorectal Liver Metastases on Intraoperative Ultrasonography
van Vledder MG, Torbenson MS, Pawlik TM, Boctor EM, Hamper UM, Olino K, Choti MA. The Effect of Steatosis on Echogenicity of Colorectal Liver Metastases on Intraoperative Ultrasonography. JAMA Surgery 2010, 145: 661-667. PMID: 20644129, DOI: 10.1001/archsurg.2010.124.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesIntraoperative ultrasonographyLiver metastasesTumor echogenicityLiver tissueExtent of steatosisEffect of steatosisCauses of steatosisFatty liver tissueJohns Hopkins HospitalNontumorous liver tissuesUltrasonography imagesSurgical therapyHistopathologic reviewLiver steatosisProspective studyHepatic steatosisSevere steatosisLiver surgeryPathological dataConspicuity of lesionsSteatosisPatientsEchogenicityUltrasonographyImmuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)
Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surgery Today 2010, 40: 404-410. PMID: 20425541, DOI: 10.1007/s00595-009-4120-8.Peer-Reviewed Original ResearchConceptsCurrent treatment modalitiesNovel therapeutic approachesGene therapySurgical resectionTreatment arsenalTumor recurrenceCancer patientsTreatment modalitiesClinical trialsTherapeutic approachesGene therapeutic strategiesVivo modelCancerImmunotherapyTherapyFurther investigationPotential additionResectionChemotherapyPatientsRecurrenceMortalityTrialsCare